$ARE

2 theses

bullish 50%neutral 0%bearish 50%

Avg return (3d)

+3.6%

Win rate (3d)

50% (2 resolved)

1d 3d 1w 1m 3m 6m 1y

Past performance does not predict future results. Informational only, not investment advice.

Recent theses

Prices as of Nov 2, 4:15 PM ET

$ARESEC Form 4bearish

Fukuzaki-Carlson Kristina · EVP - Business Operations at ALEXANDRIA REAL ESTATE EQUITIES, INC. · 48d agono track record yet

Sold 16,810 @ $50.51 avg · $849,073 · 2026-09-11

Form 4: Fukuzaki-Carlson Kristina sold ARE

Fukuzaki-Carlson Kristina (EVP - Business Operations at ALEXANDRIA REAL ESTATE EQUITIES, INC.) reported an open-market sale of 16,810 shares of ARE at an average $50.51, roughly $849,073, in a Form 4 filed 2026-09-15.

At post $52.14Now $42.57-18.4% since postedas of Nov 2, 4:15 PM ET

1d+1.1%

3d+0.7%

1w+1.7%

1m-18.8%

3m—

6m—

1y—

View filing on SEC.gov →

$AREr/wallstreetbetsYOLObullish

u/VuvuzelaSound · 184d agono track record yet

$ARE Alexandria Real Estate is the best positioned REITs for the upcoming Biotech recovery

Alexandria Real Estate is a severely undervalued life science REIT trading at ~15-year lows with NAV of ~$120 vs. current price of $41, supported by $5B cash, sustainable 7% dividend, and positioned to benefit from biotech recovery evidenced by biotech index XBI up 55.94% YoY, rising IPO activity, and new tech tenant leases.

At post $40.00Now $42.57+6.4% since postedas of Nov 2, 4:15 PM ET

1d—

3d+6.5%

1w+12.4%

1m+18.2%

3m+26.7%

6m+1.5%

1y—

original post →

End of results.